LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Latigo Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 3, 2026
$14.30+0.30 (+2.14%)
Close on Oct 19, 2026
- Market cap
- $13.37M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
About Latigo Biotherapeutics
Pharmaceutical Preparations, SIC 2834
Latigo Biotherapeutics, Inc. is listed on Nasdaq under the ticker LTGO, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Latigo Biotherapeutics, Inc.
- Headquarters
- Thousand Oaks, CA
- Address
- 1300 Rancho Conejo Blvd., Suite 305
- Phone
- (805) 716-2927
- Website
- latigobio.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- LTGO
- Exchange
- Nasdaq
- IPO date
- Aug 7, 2026
- Shares outstanding
- 66M, Sep 1, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2056611
- CUSIP
- 517954103
- ISIN
- US5179541033
- EIN
- 83-2625838
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Nima Farzan | President and CEO, Director | 114,453 |
| Neha Krishnamohan | CFO and Chief Business Officer | – |
| Neil Singla | Chief Medical Officer | – |
| Todd N. Smith | Director | – |
| Beth C. Seidenberg | Director | 4,916,374 |
| James B. Tananbaum | Director | 3,117,664 |
| Timothy P. Walbert | Director | – |
| Sara Bonstein | Director | – |
| Kevin Raidy | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 7, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 4, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |